The two-time Oscar winner announced on Twitter today that she's checking into a hospital for a heart procedure. But don't worry—she predicts she'll be back on her feet in no time.The initial EVEREST I trial reported in the Journal of the American College of Cardiology on the first 24 patients receiving the device showed four 30-day major adverse events: partial clip detachment in three patients, who underwent elective valve surgery, and one patient with post-procedure stroke that resolved at one month. Three additional patients had surgery for unresolved MR, leaving 18 patients free from surgery.
"[The procedure is] very new and involves repairing my leaky valve using a clip device, without open heart surgery, so that my heart will function better," tweeted Taylor.
"Any prayers you happen to have lying around I would dearly appreciate. I'll let you know when it's all over. Love you, Elizabeth."
More recent data on 107 patients in the US are summarized in a company press report and reported at this year's Transcatheter Cardiovascular Theraputics conference suggest favorable results with seventy-four percent of patients achieved MR reduction to 2+ or less and in 64 percent of these, MR reduction to 1+ was achieved. Additionally, there were no cases of clip embolization or procedural mortality reported. Kaplan-Meier freedom from surgery was 88.5%, 83.2% and 76.3% at 1, 2 and 3 years, respectively.
Hopefully for Ms. Taylor, things will work just as well for her.
Disclosure: I have no commercial interest in the MitraClip device.
Addendum: Early reports suggest she did fine.